Covert Hepatic Encephalopathy: Not as Minimal as You Might Think

被引:67
作者
Kappus, Matthew R.
Bajaj, Jasmohan S. [1 ,2 ]
机构
[1] Virginia Commonwealth Univ, Div Gastroenterol Hepatol & Nutr, Richmond, VA 23249 USA
[2] McGuire VA Med Ctr, Richmond, VA 23249 USA
关键词
Minimal Hepatic Encephalopathy; Cognition; Cirrhosis; Management; Liver Disease; CRITICAL FLICKER FREQUENCY; NECROSIS-FACTOR-ALPHA; QUALITY-OF-LIFE; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; BENZODIAZEPINE-RECEPTOR LIGANDS; INHIBITORY CONTROL TEST; CIRRHOTIC-PATIENTS; LIVER-CIRRHOSIS; DOUBLE-BLIND; RESPONSE-INHIBITION;
D O I
10.1016/j.cgh.2012.05.026
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatic encephalopathy (HE) is a serious neuropsychiatric and neurocognitive complication of acute and chronic liver disease. Symptoms are often overt (confusion, disorientation, ataxia, or coma) but can also be subtle (difficulty with cognitive abilities such as executive decision-making and psychomotor speed). There is consensus that HE is characterized as a spectrum of neuropsychiatric symptoms in the absence of brain disease, ranging from overt HE (OHE) to minimal HE (MHE). The West Haven Criteria are most often used to grade HE, with scores ranging from 0-4 (4 being coma). However, it is a challenge to diagnose patients with MHE or grade 1 HE; it might be practical to combine these entities and name them covert HE for clinical use. The severity of HE is associated with the stage of liver disease. Although the pathologic mechanisms of HE are not well understood, they are believed to involve increased levels of ammonia and inflammation, which lead to low-grade cerebral edema. A diagnosis of MHE requires dedicated psychometric tests and neurophysiological techniques rather than a simple clinical assessment. Although these tests can be difficult to perform in practice, they are cost effective and important; the disorder affects patients' quality of life, socioeconomic status, and driving ability and increases their risk for falls and the development of OHE. Patients with MHE are first managed by excluding other causes of neurocognitive dysfunction. Therapy with gut-specific agents might be effective. We review management strategies and important areas of research for MHE and covert HE.
引用
收藏
页码:1208 / 1219
页数:12
相关论文
共 136 条
[81]  
Norenberg MD, 1997, ADV EXP MED BIOL, V420, P95
[82]   ENDOGENOUS BENZODIAZEPINE RECEPTOR LIGANDS IN HUMAN AND ANIMAL HEPATIC-ENCEPHALOPATHY [J].
OLASMAA, M ;
ROTHSTEIN, JD ;
GUIDOTTI, A ;
WEBER, RJ ;
PAUL, SM ;
SPECTOR, S ;
ZENEROLI, ML ;
BARALDI, M ;
COSTA, E .
JOURNAL OF NEUROCHEMISTRY, 1990, 55 (06) :2015-2023
[83]  
Oppong KNW, 1997, HEPATOLOGY, V26, P870, DOI 10.1053/jhep.1997.v26.pm0009328307
[84]   Development of a clinical hepatic encephalopathy staging scale [J].
Ortiz, M. ;
Cordoba, J. ;
Doval, E. ;
Jacas, C. ;
Pujadas, F. ;
Esteban, R. ;
Guardia, J. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (06) :859-867
[85]   Minimal hepatic encephalopathy:: diagnosis, clinical significance and recommendations [J].
Ortiz, M ;
Jacas, C ;
Córdoba, J .
JOURNAL OF HEPATOLOGY, 2005, 42 :S45-S53
[86]  
PARSONSSMITH BG, 1957, LANCET, V2, P867
[87]   Hyperammonemia acts synergistically with lipopolysaccharide in inducing changes in cerebral hemodynamics in rats anaesthetised with pentobarbital [J].
Pedersen, Hans R. ;
Ring-Larsen, Helmer ;
Olsen, Niels Vidiendal ;
Larsen, Fin Stolze .
JOURNAL OF HEPATOLOGY, 2007, 47 (02) :245-252
[88]   Post-feeding hyperammonaemia in patients with transjugular intrahepatic portosystemic shunt and liver cirrhosis: role of small intestinal ammonia release and route of nutrient administration [J].
Plauth, M ;
Roske, AE ;
Romaniuk, P ;
Roth, E ;
Ziebig, R ;
Lochs, H .
GUT, 2000, 46 (06) :849-855
[89]   Inhibitory control in children with attention-deficit/hyperactivity disorder: Event-related potentials identify the processing component and timing of an impaired right-frontal response-inhibition mechanism [J].
Pliszka, SR ;
Liotti, M ;
Woldorff, MG .
BIOLOGICAL PSYCHIATRY, 2000, 48 (03) :238-246
[90]   Review article: the burden of hepatic encephalopathy [J].
Poordad, F. F. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 :3-9